Articles Tagged With: cardiovascular
-
Bempedoic Acid (Nexletol) and Bempedoic Acid and Ezetimibe (Nexlizet)
The U.S. Food and Drug Administration is expected to update the indications for bempedoic acid and bempedoic acid/ezetimibe. Esperion has submitted clinical evidence in the form of Cholesterol Lowering via Bempedoic Acid an ACL-inhibiting Regimen (CLEAR) that demonstrated that bempedoic acid was associated with a lower risk of major adverse cardiovascular events compared to placebo. Bempedoic acid and bempedoic acid/ezetimibe are distributed by Esperion as Nexletol and Nexlizet, respectively.
-
Long-Term Antiplatelet Therapy After PCI
The five-year follow-up of patients randomized to clopidogrel vs. aspirin monotherapy beyond one year after percutaneous coronary intervention has shown that clopidogrel is noninferior, but not superior, to aspirin for preventing the combined endpoint of adverse cardiovascular or major bleeding events.
-
Nitrates in Food Reduce Cardiovascular Risk
Dietary nitrates, such as in beetroot juice, improve the cardiovascular risk profile, lowering blood pressure and enhancing endothelial function.
-
How Many Steps a Day Will Improve Patients’ Longevity?
A systematic review and meta-analysis of studies of the association of step counts and cadence with all-cause mortality and cardiovascular events showed the benefits in these outcomes are statistically significant, at about 2,600 steps/day and peak at about 8,000 steps/day. Also, faster step cadence augments these benefits.
-
Major Cardiovascular Event Risk Reduction with Pitavastatin in People Living with HIV
A large randomized, controlled trial (REPRIEVE) conducted by Grinspoon and colleagues showed that in participants living with human immunodeficiency virus (HIV) who are at low-to-moderate risk for cardiovascular disease, those who received pitavastatin had a 35% lower risk of experiencing a major adverse cardiovascular event over a follow-up of approximately five years than those who received placebo.
-
Intensive Blood Pressure Control May Augment Cerebral Blood Flow
Patients with hypertension were randomized to intensive vs. standard blood pressure control and underwent baseline and follow-up cerebral perfusion imaging. Intensive blood pressure treatment was associated with improved cerebral perfusion over time.
-
New Guidance to Promote Diverse Populations in Cardiovascular Trials
Individuals who participate in randomized clinical trials should be representative of the patients who will be treated with the drugs under investigation. Unfortunately, studies have consistently shown women and those from racial and ethnic minority groups are consistently underenrolled in cardiovascular clinical trials relative to their disease burden in the population.
-
Pregnancy-Associated Stroke Is Increasing in Frequency
Stroke during pregnancy or the puerperium is a rare event but accounts for a considerable part of maternal morbidity and mortality. The incidence has been increasing in all countries, particularly in wealthy industrialized countries, where pregnancy is being delayed considerably and other cardiovascular risk factors have taken on greater importance.
-
Vitamin and Mineral Supplements for Cardiovascular Disease
A meta-analysis of systematic reviews and randomized controlled trials to analyze the role of commonly used dietary supplements for prevention and treatment of cardiovascular disease suggests no significant effect on cardiovascular outcomes or all-cause mortality, although some B vitamins appear to reduce stroke incidence, and B3 appears to increase all-cause mortality.
-
Pharmacological Therapies in HFrEF: Is Quadruple Therapy a New Standard of Care?
Approximately 50% of patients with heart failure have heart failure with reduced ejection fraction (HFrEF). HFrEF morbidity and mortality are altered favorably with the use of guideline-directed medical therapy. Multiple drug therapies have informed evidence-based therapies for the treatment of HFrEF.